1. The transitivity of bioequivalence testing: potential for drift;Anderson S;Int J Clin Pharmacol Ther,1996
2. Interchangeability of generic anti-epileptic drugs: a quantitative analysis of topiramate and gabapentin
3. European Medicine Agency (EMA).Guideline on the investigation of bioequivalence2010;1(January):1–27. Available from:https://www.ema.europa.eu/documents/scientific‐guideline/guideline‐investigation‐bioequivalence‐rev1_en.pdf
4. US Department of Health and Human Services.Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Bioavailability and bioequivalence. Studies for orally administered drug products‐general considerations.2003.
5. Health Canada.Guidance document Comparative bioavailability standards: formulations used for systemic effect. Health Canada Therapeutic Products Directorate Bureau of Policy Science and International Programs2012.https://www.canada.ca/content/dam/hc‐sc/migration/hc‐sc/dhp‐mps/alt_formats/pdf/prodpharma/applic‐demande/guide‐ld/bio/comparative-bioavailability‐standards‐formulations‐used‐systemic‐effects.pdf